These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38834171)

  • 41. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration.
    Thinggaard BS; Frederiksen K; Subhi Y; Möller S; Sørensen TL; Kawasaki R; Grauslund J; Stokholm L
    Ophthalmol Sci; 2024; 4(3):100446. PubMed ID: 38313400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The population affected by neovascular age-related macular degeneration and treated with anti-Vegf through Italian administrative healthcare data.].
    Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Dondi L; Dell'Anno I; Esposito I; Addesi A; Staurenghi G; Bandello F; Ricci F; Martini N
    Recenti Prog Med; 2023; 114(7):447-461. PubMed ID: 37392108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study.
    Korva-Gurung I; Kubin AM; Ohtonen P; Hautala N
    Pharmaceuticals (Basel); 2023 Jun; 16(7):. PubMed ID: 37513839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ganglion Cell Layer Thickness Change in Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Injections.
    Mantopoulos D; Ray H; Sanchez G; Pokroy R; Roth DB
    J Vitreoretin Dis; 2022; 6(2):126-131. PubMed ID: 37008665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retinal and choroidal changes after anti-VEGF therapy in neovascular-AMD patients: A systematic review and meta-analysis of SD-OCT studies.
    Salehi MA; Frounchi N; Zakavi SS; Mohammadi S; Harandi H; Shojaei S; Gouravani M; Fernando Arevalo J
    Surv Ophthalmol; 2024; 69(4):547-557. PubMed ID: 38641181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes.
    Blazaki S; Blavakis E; Chlouverakis G; Bontzos G; Chatziralli I; Smoustopoulos G; Dimitriou E; Stavrakakis A; Kabanarou S; Xirou T; Vavvas DG; Tsilimbaris MK
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3425-3436. PubMed ID: 37566302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.
    Pereira DS; Maturi RK; Akita K; Mahesh V; Bhisitkul RB; Nishihata T; Sakota E; Ali Y; Nakamura E; Bezwada P; Nakamura Y
    Eye (Lond); 2024 Apr; 38(6):1140-1148. PubMed ID: 38036609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.
    Ye L; Jiaqi Z; Jianchao W; Zhaohui F; Liang Y; Xiaohui Z
    Ther Adv Chronic Dis; 2020; 11():2040622320953349. PubMed ID: 32953000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.
    Khanani AM; Boyer DS; Wykoff CC; Regillo CD; Busbee BG; Pieramici D; Danzig CJ; Joondeph BC; Major JC; Turpcu A; Kiss S
    EClinicalMedicine; 2024 Jan; 67():102394. PubMed ID: 38152412
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
    Lorés-Motta L; Riaz M; Grunin M; Corominas J; van Asten F; Pauper M; Leenders M; Richardson AJ; Muether P; Cree AJ; Griffiths HL; Pham C; Belanger MC; Meester-Smoor MA; Ali M; Heid IM; Fritsche LG; Chakravarthy U; Gale R; McKibbin M; Inglehearn CF; Schlingemann RO; Omar A; Chen J; Koenekoop RK; Fauser S; Guymer RH; Hoyng CB; de Jong EK; Lotery AJ; Mitchell P; den Hollander AI; Baird PN; Chowers I
    JAMA Ophthalmol; 2018 Aug; 136(8):875-884. PubMed ID: 29852030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
    ElSheikh RH; Chauhan MZ; Sallam AB
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR; Igwe C; Jackson TL; Chong V
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004004. PubMed ID: 32844399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24.
    Hwang CK; Agrón E; Domalpally A; Cukras CA; Wong WT; Chew EY; Keenan TDL;
    Ophthalmol Retina; 2021 Feb; 5(2):108-117. PubMed ID: 33075546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options.
    Tan CS; Ngo WK; Chay IW; Ting DS; Sadda SR
    Clin Ophthalmol; 2022; 16():917-933. PubMed ID: 35368240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
    Kozak I; Gurbaxani A; Safar A; Rao P; Masalmeh A; Assaf H; Farghaly M; Pathak P; Natarajan A; Saffar I
    PLoS One; 2021; 16(7):e0254569. PubMed ID: 34255798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral blood mononuclear cells from neovascular age-related macular degeneration patients produce higher levels of chemokines CCL2 (MCP-1) and CXCL8 (IL-8).
    Lechner J; Chen M; Hogg RE; Toth L; Silvestri G; Chakravarthy U; Xu H
    J Neuroinflammation; 2017 Feb; 14(1):42. PubMed ID: 28231837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.